Clinical trials: Adenomatous Polyposis Coli (APC) Gene Mutation
- Condition Adenomatous Polyposis Coli (APC) Gene Mutation
- Funder type Industry (pharma, biotech, devices)
Familial Adenomatous Polyposis
Evaluate REC-4881 in Participants With Familial Adenomatous Polyposis (FAP)
This is a multicenter, two-part trial in participants with FAP.
- Trial name
- TUPELO (NCT05552755)
- Testing
- REC-4881
- Where
- 17 sites in United States
- Volunteers
- 67 people
- Sponsor
- Recursion Pharmaceuticals Inc.
AXIN1 Gene Mutation, APC Gene Mutation
A Study of REC-4881 in Participants With Cancers Which Have an AXIN1 or APC Mutation
This is a multi-center, open-label study to investigate the safety, efficacy and pharmacokinetics of REC-4881 (12 mg PO daily doses) for the treatment of participants with unresectable locally advanced or metastatic solid tumors…
- Conditions
- AXIN1 Gene Mutation, APC Gene Mutation, Solid Tumor
- Trial name
- NCT06005974
- Testing
- REC-4881
- Where
- 13 sites in United States
- Volunteers
- 18 people
- Sponsor
- Recursion Pharmaceuticals Inc.
Cancer, Colorectal Cancer
FOG-001 in Locally Advanced or Metastatic Solid Tumors
The goal of this clinical trial is to determine if FOG-001 is safe and effective in participants with locally advanced or metastatic solid tumors or in participants with familial adenomatous polyposis (FAP).
- Conditions
- Cancer, Colorectal Cancer, Solid Tumor, Locally Advanced Solid Tumor
- Trial name
- NCT05919264
- Testing
- FOG-001, mFOLFOX-6, Nivolumab
- Where
- 33 sites in United States, Australia
- Volunteers
- 619 people
- Sponsor
- Parabilis Medicines, Inc.